How to buy Krystal Biotech stock

Krystal Biotech, Inc is a biotechnology business based in the US. Krystal Biotech shares (KRYS) are listed on the NASDAQ and all prices are listed in US Dollars. Krystal Biotech employs 75 staff and has a market cap (total outstanding shares value) of USD$1.7 billion.

How to buy shares in Krystal Biotech

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Krystal Biotech. Find the stock by name or ticker symbol: KRYS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Krystal Biotech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Krystal Biotech, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Krystal Biotech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Krystal Biotech share price

Use our graph to track the performance of KRYS stocks over time.

Krystal Biotech shares at a glance

• Key figures

Information last updated 2021-04-15.

52-week range	USD$37.68 - USD$87.287
50-day moving average	USD$76.264
200-day moving average	USD$61.4691
Wall St. target price	USD$98.8
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.199

Buy Krystal Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Krystal Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Krystal Biotech, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Krystal Biotech financials

Gross profit TTM	USD$0
Return on assets TTM	-7.93%
Return on equity TTM	-13%
Profit margin	0%
Book value	$14.816
Market capitalisation	USD$1.7 billion

TTM: trailing 12 months

Shorting Krystal Biotech shares

There are currently 1.2 million Krystal Biotech shares held short by investors – that's known as Krystal Biotech's "short interest". This figure is 6.7% up from 1.2 million last month.

There are a few different ways that this level of interest in shorting Krystal Biotech shares can be evaluated.

Krystal Biotech's "short interest ratio" (SIR)

Krystal Biotech's "short interest ratio" (SIR) is the quantity of Krystal Biotech shares currently shorted divided by the average quantity of Krystal Biotech shares traded daily (recently around 148929.27710843). Krystal Biotech's SIR currently stands at 8.3. In other words for every 100,000 Krystal Biotech shares traded daily on the market, roughly 8300 shares are currently held short.

However Krystal Biotech's short interest can also be evaluated against the total number of Krystal Biotech shares, or, against the total number of tradable Krystal Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Krystal Biotech's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Krystal Biotech shares in existence, roughly 60 shares are currently held short) or 0.0709% of the tradable shares (for every 100,000 tradable Krystal Biotech shares, roughly 71 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Krystal Biotech.

Find out more about how you can short Krystal Biotech stock.

Krystal Biotech share dividends

We're not expecting Krystal Biotech to pay a dividend over the next 12 months.

Krystal Biotech share price volatility

Over the last 12 months, Krystal Biotech's shares have ranged in value from as little as $37.68 up to $87.287. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Krystal Biotech's is 1.1459. This would suggest that Krystal Biotech's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Krystal Biotech overview

Krystal Biotech, Inc. , a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Frequently asked questions

• What percentage of Krystal Biotech is owned by insiders or institutions?

  Currently 24.769% of Krystal Biotech shares are held by insiders and 64.307% by institutions.

• How many people work for Krystal Biotech?

  Latest data suggests 75 work at Krystal Biotech.

• When does the fiscal year end for Krystal Biotech?

  Krystal Biotech's fiscal year ends in December.

• Where is Krystal Biotech based?

  Krystal Biotech's address is: 2100 Wharton Street, Pittsburgh, PA, United States, 15203

• What is Krystal Biotech's ISIN number?

  Krystal Biotech's international securities identification number is: US5011471027

• What is Krystal Biotech's CUSIP number?

  Krystal Biotech's Committee on Uniform Securities Identification Procedures number is: 501147102